President and CEO

Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, Mr. Ciaffoni, served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Mr. Ciaffoni held various positions of increasing responsibility at Biogen Idec, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen Idec, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Mr. Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers. 


Chief Technology Officer

Dr. Alison Fleming joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Dr. Fleming is an inventor on several United States Patents and pending patent applications, and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.


Executive Vice President and Chief Financial Officer

Paul Brannelly joined Collegium Pharmaceutical in February 2015 as Executive Vice President and Chief Financial Officer. Prior to joining Collegium, Paul held senior financial management positions for both publicly held and privately held companies, gaining significant experience raising capital, executing growth strategies and mergers and acquisitions. Paul most recently served as Senior Vice President, Finance & Administration, and Treasurer of Karyopharm Therapeutics Inc., a publicly traded, clinical-stage pharmaceutical company. Prior to Karyopharm, Paul served as Vice President Finance, Treasurer, and Secretary for Verastem, Incorporated, a publicly traded biotechnology company. Earlier in his career, Paul was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund, and also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With 18 years in the biopharmaceutical industry, Paul has raised $1.0 billion in public and private capital. Paul holds a Bachelors in Business Administration in Accounting from University of Massachusetts at Amherst and was a Certified Public Accountant.


Executive Vice President and Chief Commercial Officer

Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. Scott Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. Scott has over 24 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Most recently, Scott was the Senior Vice President, Marketing and Commercial Operations for The Medicines Company, where he led all commercial functions and helped the organization advance their commercial capabilities, prepare for new product launches and strategically pivot the company through business development activities. Prior to joining The Medicines Company, Scott was the Vice President and Chief Marketing Officer-US at Biogen, leading the marketing activities for an ~$7 billion business spanning multiple therapeutic areas.  Prior to Biogen, Scott held various commercial leadership positions of increasing responsibility at Merck & Co including: VP-US Hospital and Oncology Sales and Commercial Operations, VP-US Primary Care Sales, Executive Director US Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Director of Strategic Planning and Director of Cardiovascular Marketing. Throughout his career, Scott has been involved in the commercialization of over 35 products across more than 15 therapeutic areas, and launched over 20 products. Scott received his B.S. degree in Biology from Messiah College in Grantham, PA.


Executive Vice President and General Counsel

Shirley Kuhlmann joined Collegium Pharmaceutical in March 2018 as Executive Vice President, General Counsel and Secretary. Prior to joining Collegium, Ms. Kuhlmann was an attorney in the Health Sciences Group of Pepper Hamilton LLP, a law firm headquartered in Philadelphia, PA. Ms. Kuhlmann began her career at Pepper in 2007, as an associate, and was elected a partner of that firm in 2016. Throughout her career at Pepper, Ms. Kuhlmann advised private and public companies on a range of transactional matters, including securities offerings, mergers & acquisitions, and other financing transactions. Ms. Kuhlmann received a B.A. in Economics and Political Science from Columbia University and a J.D. from the Emory University School of Law, where she was the Executive Managing Editor of the Emory Law Review.